Drug intelligence / Profile preview

dulaglutide + liraglutide

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Subcutaneous

Overview

This is a combination of two GLP-1 receptor agonists (dulaglutide and liraglutide). Both medications work by mimicking the action of the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety. Current clinical guidelines from the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) do NOT support combination therapy of multiple GLP-1 receptor agonists due to lack of added clinical benefit and potential increased risk of side effects.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on dulaglutide + liraglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dulaglutide + liraglutide.

Explore the full profile